NYSE · TMO
Thermo Fisher Scientific Inc.
$709.18+$5.03 (+0.71%)
Thermo Fisher Scientific Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.38% below the high.
Loading market information…
NYSE · A · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Agilent Technologies, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.01% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Agilent Technologies, Inc.’s forward annual dividend is $1.02 per share, paid quarterly. The forward yield is 0.56% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Agilent Technologies, Inc.’s next earnings report is currently expected on Nov 23, 2026, with estimated earnings per share of $1.72. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Agilent Technologies, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:22 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q2 2025 | May 28, 2025 | $1.31+3.97% vs estimate | $1.67B+2.54% vs estimate |
|---|
| Q1 2025 | Feb 26, 2025 | $1.31+2.34% vs estimate | $1.68B+0.66% vs estimate |
|---|
| Q4 2024 | Nov 25, 2024 | $1.46+3.55% vs estimate | $1.70B+1.7% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
41 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 14 contributors · Median target $177.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$709.18+$5.03 (+0.71%)
Thermo Fisher Scientific Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.38% below the high.
$236.94+$2.87 (+1.23%)
Danaher Corporation’s quoted price sits in the upper half of its reported 52-week range, 2.41% below the high.
$480.07+$3.19 (+0.67%)
Waters Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.46% below the high.
$1,718.61+$20.14 (+1.19%)
Mettler-Toledo International Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.58% below the high.
$165.78+$0.45 (+0.27%)
Revvity, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.94% below the high.
$50.34+$0.01 (+0.02%)
Qiagen N.V.’s quoted price sits in the upper half of its reported 52-week range, 12.94% below the high.
$384.40-$0.72 (-0.19%)
Bio-Rad Laboratories, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.99% below the high.
$62.00$0.00 (0.0%)
Bruker Corporation’s quoted price sits in the upper half of its reported 52-week range, 7.44% below the high.
